Dexmedetomidine Hydrochloride Injection, Solution, Concentrate
NDC Package 36000-262-10
Package Information
Dexmedetomidine Hydrochloride injection is none. This formulation utilizes a injection, solution, concentrate delivery system. Marketed by Baxter Healthcare Corporation, this product is identified by NDC 36000-262 and is authorized under FDA application ANDA208103.
Identification & Billing
- RxCUI: 309710 - dexmedeTOMIDine HCl 200 MCG in 2 ML Injection
- RxCUI: 309710 - 2 ML dexmedetomidine 0.1 MG/ML Injection
- RxCUI: 309710 - dexmedetomidine (as dexmedetomidine HCl) 0.1 MG/ML per 2 ML Injection
- RxCUI: 309710 - dexmedetomidine (as dexmedetomidine HCl) 100 MCG/ML Injection
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 36000 - Baxter Healthcare Corporation
- 36000-262 - Dexmedetomidine Hydrochloride
- 36000-262-10 - 10 VIAL, SINGLE-DOSE in 1 CARTON / 2 mL in 1 VIAL, SINGLE-DOSE (36000-262-01)
- 36000-262 - Dexmedetomidine Hydrochloride
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Other Available Packages
The following commercial packages are registered under the same Product NDC (36000-262). Click a package code to view its specific billing and regulatory data.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 36000-262-10 identifies a specific commercial package of 10 vial, single-dose in 1 carton / 2 ml in 1 vial, single-dose (36000-262-01) of Dexmedetomidine Hydrochloride, a human prescription drug labeled by Baxter Healthcare Corporation. This injection, solution, concentrate is formulated for intravenous use and contains dexmedetomidine hydrochloride as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Baxter Healthcare Corporation on April 16, 2026. The current certification is valid through December 31, 2027.
How is this Baxter Healthcare Corporation product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 36000026210. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.